MH Shariare, M de Matas… - International Journal of Pharmaceutics, 2011 - Elsevier Salbutamol sulphate (SS) used in dry powder inhalers requires drug particles in the respirable size range of 1–5 μm to achieve a suitable therapeutic effect. The aim of this study was therefore to determine strategies for controlling drug substance characteristics pre and post- ... Related articles - All 2 versions
D Morton, Q Zhou, L Qu, I Larson… - 1st Electron. Conf. Pharm. …, 2011 - sciforum.org Abstract: Objective: To improve the efficiency of aerosolisation in an air flow of two model micronized drug powders by dry mechanical modification of particle surfaces. Method: Two model drugs, micronized salbutamol sulphate (SS) and salmeterol xinaofoate (SX) powders ... Cached - All 2 versions
S Chono, H Suzuki, K Togami… - Drug Development …, 2011 - informahealthcare.com Purpose: The efficacy of aerosolization of ciprofloxacin (CPFX) incorporated into PEGylated liposomes (PEGylated CPFX-liposomes) for the treatment of respiratory infections was evaluated. Method: PEGylated CPFX-liposomes with 1,2-distearoyl-sn-glycero-3- ... Related articles - All 3 versions
RJ Thomas, D Webber, R Hopkins… - Applied and …, 2011 - Am Soc Microbiol This study aimed to provide data on the survival and site of damage of Escherichia coli cells following aerosolization using two different techniques, nebulization and flow focusing. Four metabolic stains were assessed for their ability to detect respiratory activities and ... Cited by 1 - Related articles - All 3 versions
AK Madl, SV Teague, Y Qu, D Masiel… - Aerosol Science and …, 2012 - Taylor & Francis Assessing the human health risks associated with engineered nanomaterials is challenging because of the wide range of plausible exposure scenarios. While exposure to nanomaterials may occur through a number of pathways, inhalation is likely one of the most significant ...
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
安全保密
